Spironolactone Ceva
spironolactone
Table of contents
Overview
The marketing authorisation for this product has been withdrawn due to the application of the sunset clause.
Authorisation details
| Product details | |
|---|---|
| Name |
Spironolactone Ceva
|
| Agency product number |
EMEA/V/C/000105
|
| Active substance |
spironolactone
|
| International non-proprietary name (INN) or common name |
spironolactone
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QC03DA01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Ceva Santé Animale
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
20/06/2007
|
| Contact address |
10 avenue de la Ballastière
33500 Libourne France |
Product information
31/10/2012 Spironolactone Ceva - EMEA/V/C/000105 - IAIN/0014
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diuretics
Therapeutic indication
For use in combination with standard therapy (including diuretic support, where necessary) for the treatment of congestive heart failure caused by valvular regurgitation in dogs.